Organisation paid for research Program year 2025 Source: CMS Open Payments

Amr Baber Research Incorporated

Neither a doctor nor a teaching hospital

Research payments

$387,215

64 payments

Through program year 2025, Amr Baber Research Incorporated is reported as receiving $387,215 in research payments, across 64 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $86,330 25
2021 Research $56,374 8
2020 Research $139,718 15
2019 Research $104,793 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $300,885 39 payments
  2. Janssen Research & Development, LLC $86,330 25 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase 4 (PMR Pediatric Gad) $134,718 14 payments
  2. Lvm-MD-14 Preapmrphase 3Double-Blind $62,515 7 payments
  3. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $56,621 14 payments
  4. Phase 4 (PMR Pediatric Gad) $54,907 5 payments
  5. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms $29,708 11 payments
  6. A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Rapastinel As Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder $20,860 2 payments
  7. A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $9,150 3 payments
  8. An Open Label, Long Term Safety Study of Rapastinel As An Adjunctive Therapy in Patients With Major Depressive Disorder MDD. $8,906 2 payments
  9. An Open Label, Long Term-Extended Access Protocol for Rapastinel As Adjunctive Or Monotherapy Treatment in Patients With Mayor Depressive Disorder $5,000 1 payment
  10. An Open-Label Long-Term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder $1,835 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record